Spinal Muscular Atrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 8 and 99 years old and have been diagnosed with androgen insensitivity syndrome (AIS), either through a genetic test showing a change in the androgen receptor gene, or through a clinical diagnosis based on specific physical and biological signs
- You identify as male or female
- You have any form of AIS — complete, partial, or mild forms are all eligible
- You are willing and able to follow all study requirements for the full length of the study
- You (or your parent/guardian if you are a child) are able to understand and sign a consent form agreeing to take part
- Adult family members of someone with AIS may also be eligible to participate
Who may not be able to join:
- People who have a similar but different condition, such as partial or complete gonadal dysgenesis, 5-alpha reductase deficiency, or another reason for a 46 XY difference of sexual development that is not AIS (confirm with trial site)
- People who have serious medical conditions that are not related to hormone or endocrine issues
- Adult relatives of AIS patients who have serious non-endocrine medical conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Veronica Gomez-Lobo, M.D., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phone: (301) 435-7567
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To define and describe a comprehensive phenotype in 500 patients with androgen insensitivity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.